STOCK TITAN

Labcorp Holdings Inc. - LH STOCK NEWS

Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.

Labcorp Holdings Inc. (NYSE: LH) is a global leader in innovative and comprehensive laboratory services, headquartered in Burlington, NC. With over 35 years of experience, Labcorp performs more than one million tests on approximately 400,000 samples daily, serving more than 220,000 clients worldwide, including physician offices, hospitals, managed care organizations, and biotechnology and pharmaceutical companies.

Labcorp operates a sophisticated laboratory network, consisting of roughly 2,000 patient-service centers. The company offers a broad range of 5,000 clinical lab tests ranging from routine blood and urine screens to complex oncology and genomic testing. Additionally, Labcorp is known for its scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology.

Recently, Labcorp has been active in expanding its operations and capabilities. For instance, it was selected as the winning bidder to acquire assets of Invitae, a leading medical genetics company, for $239 million. This acquisition is expected to bolster Labcorp's genetic specialty testing capabilities, particularly in oncology and rare diseases.

Labcorp continues to innovate, having launched the first trimester preeclampsia screening test in the U.S., which helps determine the risk of developing preeclampsia before 34 weeks of pregnancy. The company's commitment to advancing maternal and fetal health is also evident in its comprehensive preeclampsia screening offerings across all trimesters of pregnancy.

Moreover, Labcorp announced enhancements to its precision oncology portfolio, including the launch of Labcorp Tissue Complete and OmniSeq INSIGHT for ctDNA. These offerings are designed to support biopharmaceutical companies in advancing cancer research and patient care globally.

Financially, Labcorp reported first-quarter revenue of $3.18 billion in 2024, a 4.6% increase from the previous year. The company's adjusted operating income for the quarter was $452.8 million, or 14.3% of revenue. Labcorp's ongoing financial stability is demonstrated by its strong cash balance and total debt management.

Labcorp has a significant impact in the healthcare industry, supporting 84% of the new drugs and therapeutic products approved by the FDA in 2023. With over 67,000 employees serving clients in approximately 100 countries, Labcorp is dedicated to providing insights and advancing science to improve health and lives globally. To learn more about Labcorp, visit www.labcorp.com.

Rhea-AI Summary

Labcorp has announced a collaboration with Getlabs, launching Getlabs for Labcorp, an innovative at-home phlebotomy service. This service allows consumers to schedule blood draws or specimen collections at their convenience, now available in over 50 U.S. markets. The initiative aims to enhance accessibility to diagnostic testing, particularly for those with mobility challenges or busy schedules. Getlabs charges a convenience fee starting at $25, and together, they offer more than 5,000 diagnostic tests, improving health care access amid ongoing challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
none
-
Rhea-AI Summary

Labcorp (NYSE: LH) announces a strategic collaboration with Xcell Biosciences, Inc. to enhance the development of cell and gene therapies (CGTs). This partnership aims to improve the safety and efficacy of CGTs and will involve projects utilizing Xcellbio’s AVATAR incubator system. The collaboration aligns with Labcorp’s commitment to advancing CGT capabilities and supporting pharmaceutical companies in accelerating therapeutic development. Labcorp, with over 20 years of experience, has been instrumental in supporting the development of FDA-approved CAR-T cell and gene therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
none
-
News
Rhea-AI Summary

Labcorp (NYSE: LH) has declared a cash dividend of $0.72 per share, payable on June 9, 2022, to stockholders of record by May 19, 2022. This marks the initiation of quarterly dividends as part of their financial strategy. Future dividends will depend on the company's financial health, operational results, and Board discretion. Labcorp reported a revenue of $16 billion in FY2021, signaling robust performance in the life sciences sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
dividends
Rhea-AI Summary

Ventus Therapeutics has appointed Victor Lobanov, Ph.D., as Senior Vice President, Head of Computational Sciences, bringing over 25 years of experience in computational methods for drug discovery. Dr. Lobanov will lead the company's computational efforts and enhance the ReSOLVE platform while integrating machine learning and structural biology. His past roles include significant contributions at Johnson & Johnson (NYSE: JNJ) and Labcorp Drug Development (NYSE: LH). Ventus aims to leverage his expertise to optimize drug discovery processes, focusing on challenging protein targets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
management
-
Rhea-AI Summary

Labcorp (NYSE: LH) will announce its first quarter 2022 financial results on April 28, 2022, before market opens. A conference call will follow at 9 a.m. EDT to discuss these results. Interested parties can access the call by dialing the designated numbers or joining the webcast on the Labcorp Investor Relations website. An audio replay will be available until May 12, 2022. In FY2021, Labcorp reported revenue of $16 billion, showcasing its position as a leader in the life sciences sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
-
Rhea-AI Summary

Labcorp, a leading global life sciences company, is the first commercial laboratory in the U.S. to offer quantitative testing for gluten in stool samples. This innovative test, developed in collaboration with Immundiagnostik, Inc., allows individuals to accurately assess unintentional gluten consumption. With increasing awareness of celiac disease and non-celiac gluten sensitivity (NCGS), the demand for reliable testing is rising. The new test aims to provide healthcare providers and patients with critical information to better manage gluten exposure and dietary choices.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
none
Rhea-AI Summary

Labcorp (NYSE: LH) has announced a strategic partnership with Prisma Health, South Carolina's largest health system, to enhance laboratory services for patients and physicians. The collaboration involves Labcorp acquiring certain assets from Prisma's outreach lab business and providing technical support to improve hospital laboratory operations. This initiative aims to expand access to laboratory testing across South Carolina, including same-day STAT testing, and is anticipated to close in the second half of 2022, although specific transaction terms remain undisclosed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
none
-
Rhea-AI Summary

Walgreens and Labcorp have launched the nationwide availability of the Pixel by Labcorp® COVID-19 at-home collection kit, accessible at no cost to eligible individuals via Labcorp OnDemand™. This initiative, in partnership with the U.S. Department of Health and Human Services, aims to enhance testing accessibility for underserved communities. Walgreens President John Standley emphasized the importance of reducing healthcare barriers, particularly for uninsured populations. The program complements Walgreens' existing free drive-thru testing at over 7,000 locations and contributes to broader healthcare efforts amidst evolving COVID-19 conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
covid-19
-
Rhea-AI Summary

Labcorp (NYSE: LH) has successfully completed its acquisition of Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics. This strategic acquisition enhances Labcorp's liquid biopsy capabilities and expands its oncology portfolio, specifically its next-generation sequencing (NGS)-based genomic profiling products. The deal aims to improve patient outcomes in oncology. The definitive agreement was initially announced on December 23, 2021, highlighting Labcorp's commitment to advancing its diagnostics and drug development capabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Labcorp (NYSE: LH) announced its 2021 Q4 and full-year results, reporting revenues of $4.06 billion for Q4, down 9.7% year-over-year, and $16.12 billion for the full year, a 15.3% increase. Diluted EPS fell to $5.75 in Q4 from $9.54 a year prior, while full-year adjusted EPS rose to $28.52 from $23.94. The company expects a robust outlook for 2022, targeting adjusted EPS between $17.25 and $21.25 and free cash flow of $1.7 to $1.9 billion. Labcorp's oncology position will strengthen with the acquisition of Personal Genome Diagnostics and a key partnership with Ascension.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
none

FAQ

What is the current stock price of Labcorp Holdings (LH)?

The current stock price of Labcorp Holdings (LH) is $229.15 as of January 3, 2025.

What is the market cap of Labcorp Holdings (LH)?

The market cap of Labcorp Holdings (LH) is approximately 18.9B.

What does Labcorp Holdings Inc. specialize in?

Labcorp specializes in innovative and comprehensive laboratory services, including esoteric testing, genomics, and clinical and anatomic pathology.

How extensive is Labcorp's network?

Labcorp operates a sophisticated laboratory network with roughly 2,000 patient-service centers and serves over 220,000 clients worldwide.

What recent acquisitions has Labcorp made?

Labcorp recently acquired assets of Invitae, a leading medical genetics company, for $239 million to enhance its genetic specialty testing capabilities.

What new test has Labcorp launched for pregnant individuals?

Labcorp has launched the first trimester preeclampsia screening test in the U.S. to determine the risk of developing preeclampsia before 34 weeks of pregnancy.

How did Labcorp perform financially in the first quarter of 2024?

Labcorp reported first-quarter revenue of $3.18 billion in 2024, a 4.6% increase from the previous year, with an adjusted operating income of $452.8 million.

How many employees does Labcorp have?

Labcorp employs over 67,000 people who serve clients in approximately 100 countries.

What is Labcorp's involvement in the development of new drugs?

Labcorp supported 84% of the new drugs and therapeutic products approved by the FDA in 2023.

What is Labcorp's role in cancer research?

Labcorp provides comprehensive genomic profiling services like Labcorp Tissue Complete and OmniSeq INSIGHT for ctDNA to support oncology clinical trials and patient care globally.

What is unique about Labcorp's preeclampsia screening test?

Labcorp's preeclampsia screening test is the only test in the U.S. that assesses risk early in the first trimester using four key early pregnancy biomarkers.

Where can I learn more about Labcorp and its services?

You can learn more about Labcorp and its services by visiting their official website at www.labcorp.com.
Labcorp Holdings Inc.

NYSE:LH

LH Rankings

LH Stock Data

18.94B
83.33M
0.33%
94.81%
2.36%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
BURLINGTON